- Home
- JCE vs MNPR Comparison
JCE vs MNPR Comparison
Compare JCE & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JCE
- MNPR
- Stock Information
- Founded
- JCE 2007
- MNPR 2014
- Country
- JCE United States
- MNPR United States
- Employees
- JCE N/A
- MNPR N/A
- Industry
- JCE Trusts Except Educational Religious and Charitable
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- JCE Finance
- MNPR Health Care
- Exchange
- JCE Nasdaq
- MNPR Nasdaq
- Market Cap
- JCE 233.3M
- MNPR 229.2M
- IPO Year
- JCE N/A
- MNPR 2019
- Fundamental
- Price
- JCE $14.00
- MNPR $42.71
- Analyst Decision
- JCE
- MNPR Strong Buy
- Analyst Count
- JCE 0
- MNPR 5
- Target Price
- JCE N/A
- MNPR $59.50
- AVG Volume (30 Days)
- JCE 49.7K
- MNPR 23.1K
- Earning Date
- JCE 01-01-0001
- MNPR 05-08-2025
- Dividend Yield
- JCE 9.26%
- MNPR N/A
- EPS Growth
- JCE N/A
- MNPR N/A
- EPS
- JCE N/A
- MNPR N/A
- Revenue
- JCE N/A
- MNPR N/A
- Revenue This Year
- JCE N/A
- MNPR N/A
- Revenue Next Year
- JCE N/A
- MNPR N/A
- P/E Ratio
- JCE N/A
- MNPR N/A
- Revenue Growth
- JCE N/A
- MNPR N/A
- 52 Week Low
- JCE $11.64
- MNPR $1.72
- 52 Week High
- JCE $14.28
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- JCE 49.76
- MNPR 58.85
- Support Level
- JCE $13.01
- MNPR $39.35
- Resistance Level
- JCE $14.03
- MNPR $44.90
- Average True Range (ATR)
- JCE 0.59
- MNPR 3.90
- MACD
- JCE 0.09
- MNPR 0.98
- Stochastic Oscillator
- JCE 73.76
- MNPR 84.27
About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest
Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.